Published on : Nov 12, 2018
Albany, New York, November 12, 2018: Several drugs are in pipeline for the treatment of disorders associated with vision loss such as optic neuropathy, glaucoma, LHON, and optic neuritis. Nearly 10 products are under development for optic neuropathy, 13 drugs for glaucoma and over 16 drugs for LHON disease. These insights are according to the report titled “Optic Nerve Disorders Drug Development Pipeline Review, 2018,” which has been recently added to the repository of Market Research Hub (MRH).
Medical practitioners and healthcare industry experts are putting immense efforts on molecular targets for drugs development in treatment of optic nerve disorders, which include cannabinoid receptors, growth factors and kinases. Key players operating in the optic nerve disorder drug development pipeline space include Amgen, NicOx SA, and Regeneron Pharmaceuticals.
Future developments in drugs for treatment of optic nerve disorders continues to remain influenced by increasing prevalence of glaucoma, and LOHN disease worldwide. The report opines that male population is highly prone to development of LOHN compared to the female population.
Optic Nerve Disorders Drug Development Pipeline - Report Contents
The report offers an overview on the optic nerve disorders drug development worldwide, providing a detailed information on bundle of nerve fibers which transmit visual information from eyes to brain. A comprehensive intelligence on therapeutics that are under development and the market players involved in development of therapeutic drugs for treatment of optic neuropathy, Lebers hereditary optic neuropathy (LHON), glaucoma, and optic neuritis.
Scope of the report is to offer insights on companies that are most active within every pipeline, and pharmaceutical approaches that are most prominent at every stage of drug development pipeline. The report also offers information on the extent of role of institutions and universities in the pipeline, as compared to the pharmaceutical companies. Intelligence on imperative R&D milestones coupled with data publications in the area of optic nerve disorders has also been offered in the report.
Optic Nerve Disorders Drug Development Pipeline – Research Approach
Insights offered in the report on the optic nerve disorder drug development pipeline are based on a robust research approach which involves comprehensive secondary and primary researchers. Intelligence obtained from the secondary research are thoroughly validated with the help of insights obtained through the primary interviews. The data collected also goes through an expert panel validation, so as to ensure the report readers with authentic information on the optic nerve disorders drug development pipeline.
The report is acclaimed to make readers understand overall pipeline of the optic nerve disorder drug development, and offers at-a-glance overview of products in the therapeutic development for diseases indications related to optic nerve disorders. The report further aids readers in analyzing universities, institutions, and companies that are currently partaking in the optic nerve disorders drug development pipeline.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1929754
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org